Higher interferon score and normal complement levels may identify a distinct clinical subset in children with systemic lupus erythematosus

Table 5 Additional information about normocomplementemic (Normo-C) and hypocomplementemic (Hypo-C) groups

			Normo-C group		Hypo-C group
			Never Hypo-C	Previously Hypo-C	Hypo-C group
Treatment at sample collection time	Prednisone (mg/day)	Mean	15.1	2.0	19.3
		Median	7.5	0	15.0
		SD	16.9	2.7	14.4
	Hydroxychloroquine (mg/day)	Mean	296.4	310.0	250.0
		Median	300.0	300.0	225.0
		SD	104.6	89.4	108.7
SLICC Damage Index		Mean	0.4	0	0.9
		Median	0	0	0
		SD	0.5	0	1.4
BILAG-2004		Mean	4.1	3.0	11.9
		Median	2.5	2.0	9.5
		SD	4.8	3.3	9.8
Age at diagnosis (years)		Mean	12	14	10
		Median	12	14	10
		SD	3	3	2
Age at sample collection time (years)		Mean	14	15	13
		Median	13	15	14
		SD	3	3	4
Disease duration (years)		Mean	5	4	6
		Median	4	5	5
		SD	2	2	3
Complement follow-up	Months	Mean	23	21	32
		Median	15	22	20
		SD	27	13	28
	No. of measurement (until sample collection time)	Mean	4	4	6
		Median	3	3	6
		SD	4	2	4

The normocomplementemic (Normo-C) group has been divided into two subgroups: the “Never Hypo-C” and the “Previously Hypo-C”. Multiple comparisons were performed with Kruskal-Wallis non-parametric test. P values < 0.05 were considered significant (*p < 0.05). SD standard deviation

ISSN: 1478-6362